Get the Stockscreener App
0.1123
1.35%
0.0015
Propanc Biopharma Inc stock is traded at $0.1123, with a volume of 517.59K.
It is up +1.35% in the last 24 hours and down -44.27% over the past month.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
See More
Previous Close:
$0.1108
Open:
$0.114
24h Volume:
517.59K
Relative Volume:
0.29
Market Cap:
$1.78M
Revenue:
-
Net Income/Loss:
$-66.07M
P/E Ratio:
-0.00829
EPS:
-13.5424
Net Cash Flow:
$-3.11M
1W Performance:
-3.93%
1M Performance:
-44.27%
6M Performance:
-93.80%
1Y Performance:
+0.00%
1-Day Range:
$0.109
$0.1156
1-Week Range:
$0.1068
$0.1287
52-Week Range:
$0.1068
$9.36
Propanc Biopharma Inc Stock (PPCB) Company Profile
Name
Propanc Biopharma Inc
Sector
Industry
Phone
61-03-9882-0780
Address
302/6 BUTLER STREET, CAMBERWELL, VICTORIA
Compare PPCB vs PSNYW, SHMD, GOODO, DWLD, QQQE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PPCB
Propanc Biopharma Inc
|
2.87 | 244.39K | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
5.30 | 490.27M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
7.42 | 412.57M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
19.92 | 372.90M | 0 | 0 | 0 | 0.00 |
DWLD
Davis Select Worldwide ETF
|
43.93 | 0 | 0 | 0 | 0 | 0.00 |
QQQE
Direxion NASDAQ-100 Equal Weigh
|
99.50 | 0 | 0 | 0 | 0 | 0.00 |
Propanc Biopharma Inc Stock (PPCB) Latest News
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain - BioSpace
Propanc extends 17-year Spain research tie to study aging and cancer - Stock Titan
Propanc Biopharma (PPCB) approves 33M shares and 1:10–1:30 reverse split - Stock Titan
Propanc & Fyonibio Launch Assay for Phase 1b Human Study - The Clinical Trial Vanguard
PPCB Should I Buy - Intellectia AI
Propanc Biopharma (PPCB) Stock Analysis Report | Financials & Insights - Benzinga España
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy - Bitget
13% survival in pancreatic cancer; Propanc therapy hits >85% tumor inhibition - Stock Titan
Propanc Biopharma signs contract for Phase 1b cancer trial assay By Investing.com - Investing.com Canada
Propanc Biopharma contracts FyoniBio for drug assay development By Investing.com - Investing.com South Africa
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study - Bitget
Propanc Biopharma contracts FyoniBio for drug assay development - Investing.com
Propanc Biopharma signs contract for Phase 1b cancer trial assay - Investing.com
Propanc Biopharma Executes Service Agreement with FyoniBio - GlobeNewswire
Propanc Biopharma's lead asset PRP shows >85% tumor growth inhibition in preclinical pancreatic models - marketscreener.com
Propanc Biopharma highlights potential of lead asset PRP - TipRanks
Propanc Biopharma’S Lead Asset Prp Shows >85% Tumor Growth Inhibition In Preclinical Pancreatic Models - TradingView
Deadliest cancer stuck at 13% survival: new PRP therapy targets spread - Stock Titan
Propanc Biopharma appoints Dr. Ralf Brandt to board following Dr. Kenyon’s retirement By Investing.com - Investing.com South Africa
Propanc Biopharma Announces Board Change and New Appointment - TipRanks
Propanc Biopharma appoints Dr. Ralf Brandt to board following Dr. Kenyon’s retirement - Investing.com Nigeria
Propanc Biopharma (PPCB) adds oncology expert Ralf Brandt to board as Kenyon retires - Stock Titan
[EFFECT] Propanc Biopharma, Inc. SEC Filing - Stock Titan
Propanc Biopharma files four new patent applications for cancer treatment By Investing.com - Investing.com South Africa
Propanc Biopharma files four new patent applications for cancer treatment - Investing.com
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results - The Manila Times
Propanc Biopharma, Inc. SEC 10-Q Report - TradingView
Certain Warrants of Propanc Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 10-FEB-2026. - marketscreener.com
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market - The Manila Times
Lab tests: Propanc’s PRP slowed tumor growth 85%, human trial planned - Stock Titan
Propanc Biopharma files fourth patent application in two months By Investing.com - Investing.com Australia
Propanc Biopharma files fourth patent application in two months - Investing.com
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations - marketscreener.com
Propanc Biopharma Accelerates IP Momentum: Files Fourth - GlobeNewswire
PPCB Forecast — Price Prediction for 2026. Should I Buy PPCB? - Intellectia AI
Propanc Biopharma files new patent for synthetic cancer treatment - Investing.com
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - The Manila Times
Propanc Biopharma, Inc. Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - marketscreener.com
Propanc Biopharma files new patent for synthetic cancer treatment By Investing.com - Investing.com Canada
Propanc Biopharma advances pancreatic cancer treatment toward clinical trials By Investing.com - Investing.com Nigeria
PPCB (PPCB) Stock Price, News & Analysis - MarketBeat
Propanc Biopharma advances pancreatic cancer treatment toward clinical trials - Investing.com
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer - The Manila Times
Two pancreatic proenzymes could offer new options for deadly cancer - Stock Titan
Propanc Biopharma plans phase 1b trial for cancer treatment PRP By Investing.com - Investing.com Canada
Propanc Biopharma plans phase 1b trial for cancer treatment PRP - Investing.com
Propanc Biopharma Provides Shareholder Update - The Manila Times
Cancer-focused biopharma Propanc plans 2026 human trial, fibrosis work - Stock Titan
Contrasting GRAIL (NASDAQ:GRAL) and Propanc Biopharma (OTCMKTS:PPCB) - Defense World
Propanc Biopharma Receives Nasdaq Minimum Bid Price Notice - TipRanks
Propanc Biopharma Received Notice of Noncompliance - TradingView — Track All Markets
Propanc Biopharma Inc Stock (PPCB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):